Celanese Corporation
NYSE:CEChemicals
-$0.24 today
- Market cap
- $5.29B
- Beta
- 0.74
- P/E (TTM)
- -5.1
- EPS (TTM)
- -$9.98
- Dividend yield
- 0.24%
Volume 1.38M
Average 2.09M
CE Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Celanese CorporationNYSE: CE
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization growth accelerates
Q2 FY2026 depreciation & amortization of $249M rose 29.0% year over year, ahead of the +7.7% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 19.7% from the prior quarter. Over 3 fiscal years it compounded at +18.0% a year.
Context
- Depreciation & amortization amounted to 8.2% of revenue in FY2025, up 0.2 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +29.0% holds above the trailing-twelve-month pace of +7.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 786M USD
- Year-over-year change
- -4.5%
- 4-year CAGR
- +20.1%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 786M | -4.5% |
| FY2024 | 2024-12-31 | 823M | +15.8% |
| FY2023 | 2023-12-31 | 711M | +48.7% |
| FY2022 | 2022-12-31 | 478M | +26.5% |
| FY2021 | 2021-12-31 | 378M | — |
Depreciation & Amortization vs competitors
How CE compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +7.7% is the 5th highest of 11, against a peer median of -1.0%.
- Depreciation & amortization amounts to 8.7% of revenue for CE, versus a peer median of 5.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2026 | ZAR 13.32B ZAR | -4.9% | -8.5% | 5.0% | |
| LTM Jun 2026 | $842M USD | +7.7% | +18.0% | 8.7% | |
| LTM Jun 2026 | $191M USD | -33.2% | -0.6% | 10.4% | |
| LTM Jun 2026 | $180M USD | +19.2% | +1.8% | 5.0% | |
| LTM Mar 2026 | $179.26M USD | +265.2% | +115.2% | 13.8% | |
| LTM Aug 2026 | $138.46M USD | -22.6% | +6.7% | 3.9% | |
| LTM Jun 2026 | $120.49M USD | -4.1% | +4.8% | 6.2% | |
| LTM Jun 2026 | $62.19M USD | +2.1% | +5.2% | 3.7% | |
| LTM Sep 2026 | $55.23M USD | +19.4% | +24.2% | 4.8% | |
| LTM Sep 2026 | $48.82M USD | +8.8% | -4.1% | 4.4% | |
| LTM Mar 2026 | $117K USD | -65.1% | -15.5% | — | |
| Peer median (excluding CE) | — | -1.0% | +3.3% | 5.0% | |
Competitors are the stored peer set for CE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 1.89B | 1.9B | 1.96B | (1.51B) | (1.14B) |
| Depreciation & Amortization | 378M | 478M | 711M | 823M | 786M |
| Deferred Income Tax | 13M | (835M) | (967M) | 216M | (278M) |
| Stock-Based Compensation | 95M | 60M | 40M | 32M | 0 |
| Change in Working Capital | (488M) | 280M | 516M | (204M) | 235M |
| Accounts Receivables | (396M) | 218M | 105M | 92M | 213M |
| Inventory | (367M) | (253M) | 398M | 11M | 154M |
| Accounts Payables | 353M | (84M) | 20M | (234M) | 26M |
| Other Working Capital | (78M) | 399M | (7M) | (73M) | (158M) |
| Other Non-Cash Items | (131M) | (66M) | (365M) | 1.61B | 1.55B |
| Operating Cash Flow | 1.76B | 1.82B | 1.9B | 966M | 1.15B |
| Capital Expenditures | (467M) | (543M) | (568M) | (435M) | (343M) |
| Acquisitions (Net) | (1.12B) | (10.54B) | 532M | 0 | 21M |
| Purchases of Investments | 467M | 0 | 0 | 0 | 0 |
| Sales of Investments | 516M | 0 | 0 | 17M | 0 |
| Other Investing Activities | (520M) | (57M) | (98M) | (52M) | (27M) |
| Investing Cash Flow | (1.12B) | (11.14B) | (134M) | (470M) | (349M) |
| Debt Repayment | 404M | 10.78B | (1.09B) | (948M) | (323M) |
| Common Stock Issued | 0 | 0 | 0 | 1M | 0 |
| Common Stock Repurchased | (1B) | (17M) | 0 | 0 | 0 |
| Dividends Paid | (304M) | (297M) | (305M) | (307M) | (13M) |
| Other Financing Activities | (142M) | (175M) | (63M) | (59M) | (177M) |
| Financing Cash Flow | (1.04B) | 10.29B | (1.46B) | (1.31B) | (513M) |
| Effect of Forex Changes | (15M) | 4M | (12M) | (26M) | 17M |
| Net Change in Cash | (419M) | 972M | 297M | (843M) | 301M |
| Free Cash Flow | 1.29B | 1.28B | 1.33B | 531M | 803M |
Celanese Corporation
NYSE:CE
Intrinsic Alpha fair value
Locked
Current Price
$48.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.